#GI22
📢Before the meeting gets rolling, I would like to present the abstracts I am keeping my eye👁️on
My Top 10(ish) #PancreaticCancer abstracts
and
My Top 10 non-pancreatic abstracts
New @ICESOntario study led by @LevBubis & @alyson_mahar looked at patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life https://t.co/V7Xy5mVtjn
Our study in @AATSJournals looking at esophagectomy readmissions in Ontario:
1. No change in readmission rate over 13 yrs
2. Same at thoracic & non-thoracic centres
3. 18% readmitted at 'best' centre
Not all readmissions are 'bad'
https://t.co/9WtRvVmTr8
#tssmn#SoMe4Surgery
Important info on pt-reported symptom burden after #NET diagnosis now in @OncJournal. Frequent symptoms and burden persists over 5y.
Now, need to use this data to ⬆️ early & longitudinal supportive care 🦓 @CNETSCanada
Supported by @NANETS1@IRSC_CIHR
https://t.co/J16dFAyE4x
Incorporating Patient Preferences in Non-inferiority Trials: Our proposal to improve the clinical utility and interpretation of non-inferiority trials @JAMA_current@enenbee @tyler_chesney @UofTSurgery
https://t.co/0c4E1s3K6v
An assessment of 23,840 Stage I-III breast cancer patients shows high rates of symptom burden, especially in younger women, more advanced stage, lower income patients. Can we use this data to improve symptoms during treatment? https://t.co/ac1HJLbNJm
Cancer-related fatigue (CRF) is increasingly recognised as one of the most common and distressing side effects of cancer and its treatments.
It has a negative impact on work, social... https://t.co/mpa3PNE8hD
Can we improve surgical outcomes by promoting exercise, nutrition, and lifestyle modifications prior to major operations? @Sunnybrook team has created a #prehab program for cancer patients @CancerCare_ON
https://t.co/d8JJu8nNIN
Phase III trial: People with surgically removed pancreatic cancer who received mFOLFIRINOX chemo lived a median of 20 months longer than those who received gemcitabine https://t.co/3VGUA2a8DW #ASCO18
Immunoscore for the classification of #coloncancer: study provides a reliable estimate of the risk of recurrence in patients with colon cancer @sitcancer https://t.co/n3SFgZxCED